Storb et al., 1974 - Google Patents
Treatment of established human graft-versus-host disease by antithymocyte globulinStorb et al., 1974
View HTML- Document ID
- 1347497360486506140
- Author
- Storb R
- Gluckman E
- Thomas E
- Buckner C
- Cliff R
- Fefer A
- Glucksberg H
- Graham T
- Johnson F
- Lerner K
- Neiman P
- Ochs H
- Publication year
- Publication venue
- Blood
External Links
Snippet
Forty successful marrow grafts have been carried out since April 1972 for the treatment of severe refractory aplastic anemia or acute leukemia. All patients were HL-A identical and nonreactive in mixed leukocyte culture tests with the marrow donor. Nineteen of the patients …
- 206010018651 Graft versus host disease 0 title abstract description 93
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0026—Blood substitute; Oxygen transporting formulations; Plasma extender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
- A61K31/10—Sulfides; Sulfoxides; Sulfones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation; Therapies using these preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S514/00—Drug, bio-affecting and body treating compositions
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Storb et al. | Treatment of established human graft-versus-host disease by antithymocyte globulin | |
| Storb et al. | Marrow grafts between DL-A-matched canine littermates | |
| French et al. | Immunological enhancement of rat kidney grafts | |
| Storb et al. | Allogeneic marrow grafting for treatment of aplastic anemia | |
| Buckner et al. | Allogeneic marrow engraftment following whole body irradiation in a patient with leukemia | |
| DE69032484T2 (en) | COMPOSITIONS AND THE USE THEREOF TO PROMOTE IMMUNOPOTENTIATION | |
| Brown et al. | The localization of aggregated human γ-globulin in the spleens of normal mice | |
| Boranić | Transient graft-versus-host reaction in the treatment of leukemia in mice | |
| Twomey et al. | The monocytopenia of aplastic anemia | |
| Storb et al. | Paroxysmal nocturnal haemoglobinuria and refractory marrow failure treated by marrow transplantation | |
| Calne et al. | Renal transplantation in man | |
| Baumgartner et al. | Autologous bone marrow transplantation in the treatment of children and adolescents with advanced malignant tumors | |
| Ishikawa et al. | Augmentation of B16 melanoma lung colony formation in C57BL/6 mice having marked granulocytosis | |
| Pession et al. | Immunotherapy with low-dose recombinant interleukin 2 after high-dose chemotherapy and autologous stem cell transplantation in neuroblastoma | |
| Appelbaum et al. | Treatment of acute leukemia in adults with chemoradiotherapy and bone marrow transplantation | |
| Shiratori et al. | Inhibition of hepatic metastasis of colon carcinoma by asialo GM1–positive cells in the liver | |
| Kamani et al. | Bone marrow transplantation; problems and prospects | |
| Jillella et al. | Cyclophosphamide, cytosine arabinoside and TBI as a conditioning regimen for allogeneic bone marrow transplantation in patients with leukemia | |
| Harrington et al. | Acute myelogenous leukemia with eosinophilic differentiation and trisomy-1 | |
| Singh et al. | Chromosomal mutation in bone-marrow as cause of acquired granulomatous disease and refractory macrocytic anaemia | |
| Doney et al. | Recombinant granulocyte‐macrophage colony stimulating factor followed by immunosuppressive therapy for aplastic anaemia | |
| Gratwohl et al. | Methotrexate and citrovorum factor after histoincompatible allogeneic bone marrow transplants in dogs | |
| Bargetzi et al. | Recombinant human interleukin‐3 in refractory severe aplastic anaemia: a phase I/II trial | |
| JP4106488B2 (en) | Use of stem cells and CD6-depleted stem cells for induction of immune tolerance against allografts and / or treatment of leukemia | |
| Cairo et al. | The use of antithymocyte globulin in the treatment of severe aplastic anemia in children |